Exelixis shares are scheduled to resume trading at 4:35 pm ET, with quotation set to resume at 4:30 pm ET, according to Nasdaq. The stock was halted, pending news, ahead of the company announcing that the phase 3 CONTACT-01 study evaluating cabozantinib in combination with atezolizumab did not meet its primary endpoint of overall survival at the final analysis.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
